Introduction: Results from clinical trials with telotristat ethyl (TE) are really encouraging about its role in carcinoid syndrome-associated diarrhoea, however, its efficacy in flushing has been equivocal.
Aim(s): To assess the efficacy and safety of TE in patients (pts) with SBNEN, with resistant-to-treatment flushing and diarrhoea.
Materials and methods: Seventeen SBNEN pts treated with oral TE 250mg tds were included. All had ongoing symptoms, despite maximum doses of long-acting SA +/- daily sc Octreotide injections. Frequency of bowel movements (BM) and flushing were assessed in 1, 6 and 12 months. Urinary 5HIAA levels were assessed at 6 or 12 months.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr Julian Gertner
To read results and conclusion, please login ...
Further abstracts you may be interested in